NasdaqGS:BBIOBiotechs
Has BridgeBio Pharma (BBIO) Run Too Far After 112% One Year Share Price Surge?
If you are wondering whether BridgeBio Pharma's share price still reflects good value or has run too far, it helps to step back and look at what the current valuation is really telling you.
The stock last closed at US$75.25, with a 3.8% gain over the past week, a 1.3% decline over the past month, a 3.8% decline year to date, and a 112% return over the last year, plus a very large return over three years that is more than 7x.
These sharp moves have been accompanied by regular clinical and...